Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy
  • CME

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: December 14, 2021 Expiration: December 13, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca
Dirk Arnold, MD, PhD
person default
Michel Ducreux, MD, PhD
Philip Agop Philip, MD, PhD, FRCP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess BRCA1/2 and other alterations leading to homologous repair deficiency in patients with advanced pancreatic ductal adenocarcinoma
  • Apply current data and expert recommendations to optimally use platinum-based chemotherapy in patients with newly diagnosed unresectable pancreatic ductal adenocarcinoma and germline BRCA mutations
  • Plan personalized therapeutic strategies for patients with advanced pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Evaluate available data and ongoing clinical trials on emerging and investigational therapies for pancreatic ductal adenocarcinoma
  • Incorporate strategies to effectively identify and manage disease-related and treatment-related adverse events to support quality of life and continuation of therapy

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Dirk Arnold, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Pierre Fabre, and Roche; funds for research support from AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre; fees for non-CME/CE services from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pierre Fabre, and Roche; and other financial or material support from AstraZeneca.
Michel Ducreux, MD, PhD

Full Professor of Cancerology
Faculty of Medicine
University of Paris-Saclay
Department of Medicine
Gustave Roussy
Villejuif, France

Michel Ducreux, MD, PhD, has disclosed that he has received consulting fees from Amgen, Bayer, HalioDX, Ipsen, Keocyt, Lilly, Merck Serono, MSD, Roche, and Servier.
Philip Agop Philip, MD, PhD, FRCP

Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan

Philip Agop Philip, MD, PhD, FRCP, has disclosed that he has received funds for research support from Astellas, AstraZeneca, Bayer, Beigene, BMS, Corcept Therapeutics, Halozyme, Incyte, Merck, NGM Bio, Novartis, Novocure, QED, Rafeal, Syncore, Thyme; consulting fees from Blueprint, Erytech, Halozyme, Ipsen, Merck, QED, Rafael, Syncore, and TriSalus; and fees for non-CME/CE services from Astrazeneca, Bayer, Daiichi, Incyte, and Novartis.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists and other healthcare providers globally who treat patients with pancreatic cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate current and emerging therapies into the treatment of patients with pancreatic cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 14, 2021, through December 13, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Future Directions for PARP Inhibition in Pancreatic Cancer
  • CME

Loading...
Global experts provide a look ahead at emerging PARP inhibitor therapeutic strategies in the treatment of pancreatic cancer that may soon change practice.
Dirk Arnold, MD, PhD
person default
Michel Ducreux, MD, PhD
Philip Agop Philip, MD, PhD, FRCP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: December 14, 2021 Expiration: December 13, 2022

Related Content

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in biomarker testing for optimal management of advanced NSCLC

Zofia Piotrowska, MD, MHS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 27, 2022 Expired: May 26, 2023

Commentary on current molecular testing and biomarker-guided care in NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Released: May 26, 2022

Dr. Robin L. Jones offers expert commentary on TKI therapy in advanced osteosarcoma and nonadipocytic sarcoma, from Clinical Care Options (CCO)

Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: May 25, 2022

A video on providing respectful healthcare for transgender persons as illustrated through the personal transition story of Pharmacist Olivia Buckoski, from Clinical Care Options (CCO)

Olivia Buckoski, PharmD Released: May 25, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings